What is the official website of Intertek Melbourn ?

The official website of Intertek Melbourn is http://www.intertek.com/pharmaceutical/melbourn/.

What is Intertek Melbourn's cybersecurity risk score?

Intertek Melbourn has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Intertek Melbourn experienced?

According to Rankiteo, Intertek Melbourn currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Intertek Melbourn been affected by any supply chain cyber incidents ?

According to Rankiteo, Intertek Melbourn has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Intertek Melbourn have SOC 2 Type 1 certification ?

According to Rankiteo, Intertek Melbourn is not certified under SOC 2 Type 1.

Does Intertek Melbourn have SOC 2 Type 2 certification ?

According to Rankiteo, Intertek Melbourn does not hold a SOC 2 Type 2 certification.

Does Intertek Melbourn comply with GDPR ?

According to Rankiteo, Intertek Melbourn is not listed as GDPR compliant.

Does Intertek Melbourn have PCI DSS certification ?

According to Rankiteo, Intertek Melbourn does not currently maintain PCI DSS compliance.

Does Intertek Melbourn comply with HIPAA ?

According to Rankiteo, Intertek Melbourn is not compliant with HIPAA regulations.

Does Intertek Melbourn have ISO 27001 certification ?

According to Rankiteo,Intertek Melbourn is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Intertek Melbourn operate in ?

Intertek Melbourn operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Intertek Melbourn have ?

Intertek Melbourn employs approximately 105 people worldwide.

Does Intertek Melbourn own any subsidiaries ?

Intertek Melbourn presently has no subsidiaries across any sectors.

How many LinkedIn followers does Intertek Melbourn have ?

Intertek Melbourn's official LinkedIn profile has approximately 3,458 followers.

What is the NAICS classification code for Intertek Melbourn ?

Intertek Melbourn is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Intertek Melbourn have a Crunchbase profile ?

No, Intertek Melbourn does not have a profile on Crunchbase.

Does Intertek Melbourn have a LinkedIn profile ?

Yes, Intertek Melbourn maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/intertek-melbourn.

How many cybersecurity incidents has Intertek Melbourn experienced ?

As of August 20, 2026, Rankiteo reports that Intertek Melbourn has not experienced any cybersecurity incidents.

How many peer or competitor companies does Intertek Melbourn have ?

Intertek Melbourn has an estimated 5,728 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Intertek Melbourn

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Intertek Melbourn Vendor Cyber Rating & Cyber Score

intertek.com

Add Your Compliance Badge

A leading provider of pharmaceutical analysis and formulation support with 30+ years of experience in inhaled product development and Good Manufacturing Practice (GMP) compliant analytical testing and stability storage services. We have a reputation for providing outstanding and responsive customer service. Previously known as Melbourn Scientific Ltd, the laboratory, based near Cambridge UK, was acquired by Intertek in 2013. We opened a second facility in 2015 and another in 2019 leading to further expansion which has doubled our laboratory footprint. We have specialist skills and experience in analytical testing and formulation for inhaled and intranasal products as well as all other dosage forms for healthcare products. Clients include

Intertek Melbourn A.I CyberSecurity Scoring

Scoring History

Intertek Melbourn

Intertek Melbourn CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Intertek Melbourn Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Intertek Melbourn

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intertek Melbourn in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Intertek Melbourn in 2026.

Incident Types Intertek Melbourn vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intertek Melbourn in 2026.

Incident History - Intertek Melbourn (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Intertek Melbourn Subsidiaries

Intertek Melbourn

Pharmaceutical Manufacturing

Website: http://www.intertek.com/pharmaceutical/melbourn/

Company Size: 105

IntertekInternational Trade and Development

Intertek BrazilInternational Trade and Development

Intertek BangladeshInternational Trade and Development

Intertek LatinoaméricaInternational Trade and Development

Intertek Middle EastInternational Trade and Development

Intertek FranceInternational Trade and Development

Intertek EnergyOil and Gas

Professional Service Industries, Inc. (PSI)Civil Engineering

Intertek SpainInternational Trade and Development

Intertek Business AssuranceInternational Trade and Development

Intertek ElectricalAppliances, Electrical, and Electronics Manufacturing

Intertek Agriculture & FoodFood and Beverage Manufacturing

Intertek AssurisConsumer Goods

Intertek SustainabilityInternational Trade and Development

Intertek Greater ChinaInternational Trade and Development

Intertek Softlines and HardlinesRetail

Intertek SwedenInternational Trade and Development

Intertek Transportation TechnologiesMotor Vehicle Manufacturing

Intertek Pharmaceutical ServicesPharmaceutical Manufacturing

Intertek DeutschlandBusiness Consulting and Services

Intertek MineralsMining

Intertek Government and Trade ServicesInternational Trade and Development

Intertek Chemicals & Materials - Laboratory Testing ServicesChemical Manufacturing

Intertek Cosmetics & Consumer HealthcareRetail Health and Personal Care Products

Intertek LintecInternational Trade and Development

Loading…

Intertek Melbourn Similar Companies

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

Intertek Melbourn CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-76929

SUMMARY

Pcapng file parser crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service

Published

Date2026-08-19

Updated

Date2026-08-19

RISK INFORMATION (Score: 4.7)

cvss3

Base Score: 4.7

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:N/UI:R/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

REFERENCES

CVE-2026-76928

SUMMARY

X.509IF protocol dissector crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service

Published

Date2026-08-19

Updated

Date2026-08-19

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-76927

SUMMARY

H.245 protocol dissector crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service

Published

Date2026-08-19

Updated

Date2026-08-19

RISK INFORMATION (Score: 4.7)

cvss3

Base Score: 4.7

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:N/UI:R/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

REFERENCES

CVE-2026-76926

SUMMARY

BUSMASTER file parser abnormal exit in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service

Published

Date2026-08-19

Updated

Date2026-08-19

RISK INFORMATION (Score: 3.1)

cvss3

Base Score: 3.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

1.6

REFERENCES

CVE-2026-76924

SUMMARY

Kerberos protocol dissector crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service

Published

Date2026-08-19

Updated

Date2026-08-19

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…